Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
V. Tabar, H. Sarva, A. M. Lozano, A. Fasano, S. K. Kalia, K. K. H. Yu, C. Brennan, Y. Ma, S. Peng, D. Eidelberg, M. Tomishima, S. Irion, W. Stemple, N. Abid, A. Lampron, L. Studer & C. Henchcliffe
For millions of people living with Parkinson’s disease, dopamine-producing cells in the brain are slowly and silently disappearing.
Parkinson’s disease is characterized by the progressive loss of these dopamine-producing neurons. As dopamine levels decline, people develop many of the life-altering symptoms associated with the condition, including tremors, movement difficulties, and sleep disturbances.
Over the past several decades, important advances have been made in treating Parkinson’s disease. Therapies such as levodopa (L-dopa) help replenish dopamine levels, while deep brain stimulation (DBS) helps regulate brain signaling. However, these approaches do not address the root of the problem: the degeneration of brain cells.
What if healthy cells could replace those that have been lost?

BlueRock Therapeutics is exploring that possibility with bemdaneprocel (bem-day-n-pro-sell) an investigational cell therapy for Parkinson’s disease. Bemdaneprocel is a “living medicine.” It uses specially prepared cells designed to develop into dopamine-producing neurons once surgically placed in the brain. The goal for these cells is to integrate and restore dopamine production in the patient’s brain.
In a Phase I clinical trial conducted in 2024 with 12 participants, no serious safety concerns were reported, and early findings suggested possible improvements in movement symptoms over two years of follow-up.
While these results are encouraging, the research is still in its early stages. Larger clinical trials are needed to better understand safety, dosing, and overall effectiveness. Still, this approach highlights an emerging direction in medicine: using human cells as living therapies to address the root causes of neurodegenerative disease. This work has the potential to improve quality of life for the millions of people living with Parkinson’s disease.